About Regenexx

Today Regenexx is known as the “Trusted Alternative to Orthopedic Surgery,” with 100 Regenexx affiliates and over 110 highly trained physicians treating dozens of orthopedic conditions without surgery.

Our research-based methods and patented protocol allow our doctors to concentrate cells and apply them precisely to injured areas. The goal of each procedure is to reduce pain and improve function by promoting the body’s own ability to heal naturally.

Our Story

In 2005, Dr. Chris Centeno and Dr. John Schultz, physicians in a small two-person pain management clinic in Colorado, pioneered the specialty of Interventional Orthopedics. They were the first in the world to apply stem cells from bone marrow concentrate to treat many orthopedic injuries. Two years later, they completed a two-year, IRB-approved research study of the use of both culture-expanded and same-day stem cells to treat knee and hip arthritis and low-back degenerative disc disease.

Photo of Regenexx founders Dr. Chris Centeno and Dr. John Schultz wearing blue medical scrubs and looking towards the camera.

Regenexx founders Dr. Chris Centeno and Dr. John Schultz

We continuously innovate through research, development, and training. Regenexx has introduced many of the processing and treatment techniques used in the field today. We have also published a large part of all research on the use of bone marrow concentrate for the treatment of orthopedic injuries.

Regenexx Milestones

  • 2020: Regenexx publishes second randomized control trial on shoulder rotator cuff tears

  • 2019: The Regenexx network reaches 62 locations

  • 2016: Regenexx publishes the world’s largest stem cell safety paper in any medical indication

  • 2014-2017: First randomized control trial for knee arthritis completed

  • 2011: The first physician joins the Regenexx network

  • 2009: World-class lab unveiled at Regenexx headquarters, led by a doctorate-level research team publication

  • 2007: Dr. Chris Centeno and Dr. John Schultz complete a two-year, IRB-approved research study of the use of both culture-expanded and same-day stem cells to treat knee and hip arthritis and low-back degenerative disc disease

  • 2006: Regenexx’s first research is published

  • 2005: Regenexx starts its Patient Registry– a database for tracking patient outcomes

TO TOP
livechat button